United Immunity Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$14M
- Investors
-
22
United Immunity General Information
Description
Developer of nanoparticles and lipid nanoparticles (LNPs) designed to target myeloid cells to treat cancer and infectious diseases. The company's platform delivers various therapeutic agents directly to macrophages and dendritic cells, enabling researchers to develop treatments for conditions including cancer, autoimmune diseases, fibrosis, and infectious diseases.
Contact Information
Website
www.unitedimmunity.co.jpCorporate Office
- 1-12-3 Nihonbashi-Muromachi
- Chuo-ku
- Tokyo, 103-0022
- Japan
Corporate Office
- 1-12-3 Nihonbashi-Muromachi
- Chuo-ku
- Tokyo, 103-0022
- Japan
United Immunity Timeline
United Immunity Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 24-Sep-2026 | $14M | Completed | Clinical Trials - Phase 2 | ||
| 12. Grant | 24-Sep-2026 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC | 01-Jun-2026 | Completed | Clinical Trials - Phase 2 | |||
| 10. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 9. Later Stage VC | 18-Mar-2024 | Completed | Clinical Trials - Phase 2 | |||
| 8. Accelerator/Incubator | 12-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series B) | 01-Aug-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Early Stage VC (Series B) | 07-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A2) | 31-Mar-2021 | $931K | $1.67M | Completed | Clinical Trials - Phase 1 | |
| 4. Grant | 04-Jan-2021 | $3M | $744K | Completed | Clinical Trials - Phase 1 |
United Immunity Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Preferred | ||||||||
| B2 Preferred | ||||||||
| A2 Preferred | 225 | $3189.93 | $3189.93 | 1x | $3189.93 | 11.76% | ||
| A Preferred | 241 | $2392.44 | $2392.44 | 1x | $2392.44 | 12.59% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
United Immunity Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
United Immunity Patents
United Immunity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024283556-A1 | Complex | Pending | 01-Jun-2023 | ||
| EP-4578448-A1 | Complex | Pending | 01-Jun-2023 | ||
| EP-4578448-A4 | Complex | Pending | 01-Jun-2023 | ||
| JP-7576899-B1 | Complex | Active | 01-Jun-2023 | ||
| US-12685779-B2 | Complex | Active | 01-Jun-2023 | A61K47/61 |
United Immunity Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
United Immunity Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Itochu | Corporation | Minority | ||
| Kobe University Capital | Venture Capital | Minority | ||
| Miyako Capital | Venture Capital | Minority | ||
| Mizuho Capital | Venture Capital | Minority | ||
| Ono Venture Investment | Corporate Venture Capital | Minority |
United Immunity Investments (1)
United Immunity’s most recent deal was a Corporate Asset Purchase with Carisma Therapeutics (Macrophage Assets for the Treatment of Cancer and Liver Fibrosis). The deal was made on 21-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carisma Therapeutics (Macrophage Assets for the Treatment of Cancer and Liver Fibrosis) | 21-May-2026 | Corporate Asset Purchase | Buildings and Property |
United Immunity FAQs
-
When was United Immunity founded?
United Immunity was founded in 2017.
-
Where is United Immunity headquartered?
United Immunity is headquartered in Tokyo, Japan.
-
What is the size of United Immunity?
United Immunity has 17 total employees.
-
What industry is United Immunity in?
United Immunity’s primary industry is Biotechnology.
-
Is United Immunity a private or public company?
United Immunity is a Private company.
-
What is United Immunity’s current revenue?
The current revenue for United Immunity is .
-
How much funding has United Immunity raised over time?
United Immunity has raised $27.8M.
-
Who are United Immunity’s investors?
Itochu, Kobe University Capital, Miyako Capital, Mizuho Capital, and Ono Venture Investment are 5 of 22 investors who have invested in United Immunity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
